Literature DB >> 8491409

Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?

A Rhodes1, J B Eastwood, S A Smith.   

Abstract

A 72 year old white man developed acute hepatic impairment and renal failure within 24 hours of starting intravenous amiodarone for paroxysmal ventricular tachycardia. After normal initial investigations, there was a noticeable rise in serum transaminases as well as an increase in clotting times, a decrease in renal function and a thrombocytopenia. These changes returned to normal within seven days of withdrawal of the drug without specific treatment, and the patient was later treated with oral amiodarone without any further evidence of hepatotoxicity. Intravenous amiodarone has been implicated in acute hepatic disease on four previous occasions, but it is suggested that polysorbate 80, an organic surfactant added to the intravenous infusion, is a more likely cause of this complication. Similar reactions have been described with polysorbate 80 in association with the 'E-ferol' syndrome in infants. The occurrence of acute hepatic impairment with intravenous amiodarone does not necessarily preclude the use of this drug by mouth.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491409      PMCID: PMC1374323          DOI: 10.1136/gut.34.4.565

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  6 in total

1.  Acute hepatic dysfunction following parenteral amiodarone administration.

Authors:  R N Stevenson; T H Nayani; J R Davies
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

2.  Long-term hepatic tolerance of amiodarone in the clinic.

Authors:  G Plomteux; C Heusghem; H Ernould; N Vandeghen
Journal:  Eur J Pharmacol       Date:  1969-12       Impact factor: 4.432

3.  Side effects of long-term amiodarone therapy.

Authors:  L Harris; W J McKenna; E Rowland; D W Holt; G C Storey; D M Krikler
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

4.  Probable early acute hepatitis with parenteral amiodarone.

Authors:  J Lupon-Rosés; R Simó-Canonge; L Lu-Cortez; G Permanyer-Miralda; H Allende-Monclús
Journal:  Clin Cardiol       Date:  1986-05       Impact factor: 2.882

5.  Adverse reactions during treatment with amiodarone hydrochloride.

Authors:  B McGovern; H Garan; E Kelly; J N Ruskin
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-16

6.  Acute hepatitis after parenteral amiodarone administration.

Authors:  M Pye; R J Northcote; S M Cobbe
Journal:  Br Heart J       Date:  1988-06
  6 in total
  20 in total

1.  Acute thrombocytopenia in patients treated with amiodarone is caused by antibodies specific for platelet membrane glycoproteins.

Authors:  Mervyn A Sahud; Michael Caulfield; Nigel Clarke; Robert Koch; Daniel Bougie; Richard Aster
Journal:  Br J Haematol       Date:  2013-08-19       Impact factor: 6.998

2.  Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy.

Authors:  P R James; S M Hardman
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

3.  Acute hepatic failure following intravenous amiodarone.

Authors:  Robert Grecian; Mark Ainslie
Journal:  BMJ Case Rep       Date:  2012-12-18

4.  Acute hepatitis after amiodarone infusion.

Authors:  Paulo Fonseca; Adelaide Dias; Helena Gonçalves; Aníbal Albuquerque; Vasco Gama
Journal:  World J Clin Cases       Date:  2015-10-16       Impact factor: 1.337

Review 5.  Adverse drug events related to dosage forms and delivery systems.

Authors:  I F Uchegbu; A T Florence
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

Review 6.  Ventricular tachycardia associated with radiation-induced cardiac sarcoma.

Authors:  Elijah H Beaty; Wassim Ballany; Richard G Trohman; Christopher Madias
Journal:  Tex Heart Inst J       Date:  2014-12-01

7.  Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy.

Authors:  Mounia Lahbabi; Nouredine Aqodad; Adil Ibrahimi; Mryem Lahlou; Hafid Aqodad
Journal:  World J Hepatol       Date:  2012-06-27

Review 8.  Class III antiarrhythmics in overdose. Presenting features and management principles.

Authors:  E W Leatham; D W Holt; W J McKenna
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

9.  Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant.

Authors:  Jennifer S Kicker; Julie A Haizlip; Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2012-04

10.  Hepatic Dysfunction in Patients Receiving Intravenous Amiodarone.

Authors:  Ali Hashmi; Nicole R Keswani; Sharon Kim; David Y Graham
Journal:  South Med J       Date:  2016-02       Impact factor: 0.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.